Answers are grounded in this paper and cite their sources.
Background Diabetic retinopathy (DR) has been linked to an elevated risk of mortality among individuals with diabetes. This study aimed to investigate the association of DR with mortality and to evaluate whether glycemic variability mediates this association. Methods This retrospective cohort study utilized data from the Diabetes Care Management Program database in Taiwan and included 21,740 patients with type 2 diabetes (T2D) enrolled between 2001 and 2020, with follow-up through 2021. Diabetic retinopathy was assessed using fundus photography. Cox proportional hazards regression models were applied to examine the associations of DR with mortality outcomes. Mediation analyses were performed to estimate the proportion of these associations attributable to glycemic variability. Results At baseline, 5,022 participants (23.1%) had diabetic retinopathy. Over a mean follow-up of 8.47 years, 4,596 deaths (21.1%) were documented, including 2,141 from expanded cardiovascular disease (CVD) and 2,455 from non-expanded CVD causes. After multivariable adjustment, including either coefficient of variation of fasting plasma glucose (FPG-CV) or HbA1c-CV, DR was significantly associated with higher risks of all-cause mortality (hazard ratio [HR] 1.30, 95% confidence interval [CI] 1.21–1.38; and 1.33, 1.24–1.42, respectively), expanded CVD mortality (1.44, 1.31–1.58; and 1.47, 1.34–1.61, respectively), and non-expanded CVD mortality (1.17, 1.07–1.28; and 1.20, 1.10–1.32, respectively). Mediation analyses demonstrated that FPG-CV acted as the predominant mediator, accounting for 10.74%, 7.88%, and 16.66% of the associations of DR with all-cause, expanded CVD, and non-expanded CVD mortality, respectively, whereas HbA1c-CV exhibited overall non-significant or relatively modest mediating effects. Conclusions Variability in FPG emerged as the predominant mediator of the associations of DR with both all-cause and cause-specific mortality in patients with T2D, underscoring the clinical value of monitoring fasting glycemic stability. Clinical trial number Not applicable
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: